HighGravityDataAmgen — Nov 4, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-25-000070
Showing in the filing
EPS (non-GAAP basis)
“$20.60 to $21.40”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 8
Dividend for Q3 FY2025
“$2.38 per share”
Total revenues for FY2025
“$35.8 billion to $36.6 billion”
EPS (GAAP basis) for FY2025
“$13.76 to $14.60”
Tax rate (GAAP basis) for FY2025
“14.5% to 16.0%”
EPS (non-GAAP basis) for FY2025
“$20.60 to $21.40”
Tax rate (non-GAAP basis) for FY2025
“15.0% to 16.5%”
Capital expenditures for FY2025
“$2.2 billion to $2.3 billion”
Share repurchases for FY2025
“not to exceed $500 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
$Billions, except shares Q3 ’25 Q3 ’24 YOY Δ Operating Cash Flow $ 4.7 $ 3.6 $ 1.1 Capital Expenditures $ 0.4 $ 0.3 $ 0.2 Free Cash Flow $ 4.2 $ 3.3 $ 0.9 Dividends Paid $ 1.3 $ 1.2 $ 0.1 Share Repurchases $ 0.0 $ 0.0 $ 0.0 Average Diluted Shares (millions) 542 542 0 Note: Numbers may not add due to rounding AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Page 7 $Billions 9/30/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 9.4 $ 12.0 $ (2.5) Debt Outstanding $ 54.6 $ 60.1 $ (5.5) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $35.8 billion to $36.6 billion. • On a GAAP basis, EPS in the range of $13.76 to $14.60, and a tax rate in the range of 14.5% to 16.0%. • On a non-GAAP basis, EPS in the range of $20.60 to $21.40, and a tax rate in the range of 15.0% to 16.5%. • Capital expenditures in the range of $2.2 billion to $2.3 billion. • Share repurchases not to exceed $500 million. This guidance includes the estimated impact of implemented tariffs, but does not account for any tariffs or potential pricing actions announced or described but not implemented as well as any tariffs, sector specific tariffs, or pricing actions that could be implemented in the future. Third Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). • MARITIME-1, a Phase 3 study of MariTide for chronic weight management, has completed enrollment of adults living with obesity or overweight, without Type 2 Diabetes (T2D). • MARITIME-2, a Phase 3 study of MariTide for chronic weight management, has completed enrollment of adults living with obesity or overweight, with T2D. • MARITIME-CV, a Phase 3 study o
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.